🔎 Trials Near Me

Beranda › Kanker Paru › New York › Greenburgh

Uji klinis Kanker Paru di Greenburgh, NY

17 studi untuk Kanker Paru mencari peserta di lokasi sekitar Greenburgh (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Menerima pesertaFase 3
  • Phelps Memorial Hospital Center, Sleepy Hollow · 4 mi jauhnya
  • Dickstein Cancer Treatment Center, White Plains · 4 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT04267848

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Menerima pesertaFase 3
  • Dickstein Cancer Treatment Center, White Plains · 4 mi jauhnya
  • Memorial Sloan Kettering Bergen, Montvale · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT04181060

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Menerima pesertaFase 2
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04991025

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Menerima pesertaFase 2
  • MSK Westchester, East White Plains · 5 mi jauhnya
  • MSK Bergen., Montvale · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07476287

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Menerima pesertaFase 3
  • White Plains Hospital ( Site 0091), White Plains · 4 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Menerima pesertaFase 3
  • Hematology Oncology Associates of Rockland, Nyack · 6 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07222566

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Menerima pesertaFase 3
  • Hematology Oncology Associates of Rockland, Nyack · 6 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06758401

A Registry for People With Lung Cancer

Menerima pesertaStudi observasional
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06424327

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Menerima pesertaFase 2/3
  • WMCHealth Advanced Physician Services, Hawthorne · 6 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07063745

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Menerima pesertaFase 2/3
  • White Plains Hospital, White Plains · 4 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06712316

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Menerima pesertaFase 3
  • White Plains Hospital, White Plains · 4 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06712355

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Menerima pesertaFase 3
  • Westchester Medical Center, Valhalla · 5 mi jauhnya
  • Memorial Sloan Kettering Bergen, Montvale · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05624996

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Menerima pesertaFase 3
  • Memorial Sloan Kettering Bergen, Montvale · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06500481

A Study of Lung Cancer Risk

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale · 9 mi jauhnya
Usia 40 hingga 74 · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT07701733

A Study of a Side Effects and Resource Navigation Program for People With Cancer

Menerima peserta
  • Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07646847

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

Menerima pesertaFase 2
  • Memorial Sloan Kettering Bergen, Montvale · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT05419076

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • Memorial Sloan Kettering Bergen, Montvale · 9 mi jauhnya
18 Minutes · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06031688

Uji klinis Kanker Paru di kota lain

Studi lain di Greenburgh

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.